Pulmo BioTech Inc is a development stage public company which intends to bring innovative
and exciting molecular imaging medical diagnostic technologies to the marketplace.
Our current product candidate is a molecular imaging molecule which is designed for
the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory
The brand name for our product candidate is “PulmoBind”.
We have completed Pre-Clinical trials of PulmoBind and are anticipating starting
Phase I Human Trials shortly.
If PulmoBind is successful in its Phase Trials, we believe that it will quickly replace
the incumbent technology for the Nuclear Medicine based diagnosis of Pulmonary Embolism,
and will further create new markets for the diagnosis of Pulmonary Hypertension,
Chronic Obstructive Pulmonary Disorder (COPD) and other disorders afflicting the
pulmonary circulatory system.